Cargando…

P1417: BASELINE CALCIUM WAS ASSOCIATED WITH PROGNOSIS AFTER CAR T-CELL THERAPY

Detalles Bibliográficos
Autores principales:	Wang, Xindi, Hu, Yu, Mei, Heng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430711/ http://dx.doi.org/10.1097/01.HS9.0000972556.45906.0a

Ejemplares similares

P1404: IL-10 PLUS THE EASIX SCORE PREDICT BLEEDING EVENTS AFTER ANTI-CD19 CAR T-CELL THERAPY
por: Wang, Xindi, et al.
Publicado: (2023)

P1417: PROPHYLACTIC NAC PROMOTED HEMATOPOIETIC RECONSTITUTION BY IMPROVING ENDOTHELIAL CELLS AFTER HSCT: A PHASE 3, OPEN-LABEL RANDOMIZED TRIAL
por: Wang, Y., et al.
Publicado: (2022)

P1393: BISPECIFIC CD19/CD37 CAR-T CELLS IN PATIENTS WITH REFRACTORY OR RELAPSED B-CELL LYMPHOMA
por: Luo, Wenjing, et al.
Publicado: (2023)

1417. Fosfomycin Use in the Treatment of Complicated Urinary Tract Infections at a Veterans Affairs Medical Center
por: Lee, Ryan, et al.
Publicado: (2021)

P1363: NOVEL DUAL-TARGETING AND SURFACE-ENGINEERED BIO-ORTHOGONALLY LENTIVIRAL VECTORS FOR IN VIVO CAR-T CELLS GENERATION
por: Chen, Zhaozhao, et al.
Publicado: (2023)

P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE
por: Bücklein, V., et al.
Publicado: (2022)

1417. Clinical Features and Outcomes of raoultella terrigena Infections. A Single-Center Experience from Karachi, Pakistan
por: Ahmed, Ishfaque, et al.
Publicado: (2020)

ACCEPTANCE OF PREMARITAL HEALTH COUNSELING IN RIYADH CITY, 1417H
por: Al-Kahtani, Nabil H.
Publicado: (2000)

IL-10 plus the EASIX score predict bleeding events after anti-CD19 CAR T-cell therapy
por: Wang, Xindi, et al.
Publicado: (2023)

P1522: PERIPHERAL BLOOD SMEARS DISTINGUISH INFECTIVE FEVER AFTER CAR-T THERAPY
por: He, Shaolong, et al.
Publicado: (2023)

Genome sequence of the lupin-nodulating Bradyrhizobium sp. strain WSM1417
por: Reeve, Wayne, et al.
Publicado: (2013)

P1442: DYNAMIC LANDSCAPE OF PLASMA PROTEOME AND METABOLOME IN B-ALL PATIENTS DURING CAR-T CELL THERAPY
por: Wu, J., et al.
Publicado: (2022)

P1168: DURABLE REMISSION AFTER SEQUENTIAL CD19/20 CAR T-CELL “CAKE-ICING” THERAPY OCCURRED IN REFRACTORY/RELAPSED DLBCL
por: Zheng, Peihao, et al.
Publicado: (2023)

P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF THE KARMMA TRIAL
por: Rodríguez-Otero, P, et al.
Publicado: (2022)

P1376: IDENTIFICATION OF SURFACEOME CHANGES IN CD19 CAR-T THERAPY-RESISTANT LYMPHOMA CELLS
por: Krawczyk, Marta, et al.
Publicado: (2023)

P1687: LIFE AFTER CAR T-CELLS: DO PATIENTS RECOVER A NORMAL LIFE?
por: Perthus, Alya, et al.
Publicado: (2023)

P1413: DOES TOCILIZUMAB INCREASE THE RISK OF INFECTIONS IN PATIENTS UNDERGOING CAR-T THERAPY?
por: Greenhalgh, Sophie, et al.
Publicado: (2023)

P944: A PHASE I STUDY OF C-CAR088, A NOVEL HUMANIZED ANTI-BCMA CAR T CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Qu, X., et al.
Publicado: (2022)

P1412: CLINICIAN LED NUTRITIONAL ASSESSMENT AND PRE-OPTIMISATION OF PATIENTS UNDERGOING CAR-T CELL THERAPY
por: Awofisayo, Olateni, et al.
Publicado: (2023)

P1441: SINGLE-CELL TRANSCRIPTOMIC CHARACTERIZATIONS OF BONE MARROW MONONUCLEAR CELLS AND CAR-T PRODUCTS ASSOCIATED WITH EFFICACY AND TOXICITY IN B-ALL PATIENTS
por: Du, M., et al.
Publicado: (2022)

P64 A CASE OF COVID-19 PNEUMONIA AFTER CAR T-CELL THERAPY IN A PATIENT AFFECTED BY RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Ielo, C., et al.
Publicado: (2023)

P616: LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL
por: Liang, Emily, et al.
Publicado: (2023)

Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy
por: Li, Chenggong, et al.
Publicado: (2020)

P1540: COVID-19 INFECTION AMONG CAR-T CELL THERAPY RECIPIENTS: A SINGLE CENTER EXPERIENCE
por: Din, Mohammad Ammad Ud, et al.
Publicado: (2023)

P977: BISPECIFIC CS1-BCMA CAR-T CELLS ARE CLINICALLY ACTIVE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Li, C., et al.
Publicado: (2022)

P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
por: Rejeski, K., et al.
Publicado: (2022)

Case Report: ITP Treatment After CAR-T Cell Therapy in Patients With Multiple Myeloma
por: Du, Mengyi, et al.
Publicado: (2022)

P1414: CRP IS A CONVENIENT PREDICTIVE MARKER OF THE ANTIPYRETIC EFFECT OF TOCILIZUMAB ON CRS DURING CAR-T CELL THERAPY
por: Yokoyama, Shota, et al.
Publicado: (2023)

P1448: LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY
por: Derigs, P., et al.
Publicado: (2022)

P1462: POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD EXPERIENCE
por: Spanjaart, A. M., et al.
Publicado: (2022)

5,8-Dibromo-14,17-difluoro-2,11-dithia[3.3]paracyclophane
por: Hao, Xiaowei, et al.
Publicado: (2010)

1417. Detection of Human Herpesviruses DNA in Cerebrospinal Fluids of Patients Suspected with Central Nervous System Infection
por: Higashimoto, Yuki, et al.
Publicado: (2019)

P1170: CAR-T THERAPY IS EFFECTIVE AND SAFE IN TREATING RELAPSED/REFRACTORY LYMPHOMA WITH MALIGNANT SEROUS CAVITY EFFUSION
por: Huang, Lefu, et al.
Publicado: (2023)

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies
por: Zhang, Yinqiang, et al.
Publicado: (2023)

P23: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY.
por: Fazio, F, et al.
Publicado: (2022)

P902: RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY
por: Fazio, F., et al.
Publicado: (2022)

P357: DECITABINE CONSOLIDATION AFTER CD19/CD22 CAR-T THERAPY IS A NOVEL STRATEGY TO IMPROVE OUTCOMES IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
por: LI, Tingting, et al.
Publicado: (2023)

P1411: FIRST EVALUATION OF A MOBILE HEALTH APP DEVELOPED TO MONITOR ACUTE TOXICITIES AFTER CAR T-CELL THERAPY: A THINK ALOUD STUDY WITH PATIENT EXPERTS
por: Kos, Milan, et al.
Publicado: (2023)

P1450: AUTOLOGOUS STEM CELL TRANSPLANTATION INDUCES HIGHER LEVEL OF EXHAUSTED T-CELLS IN DLBCL PATIENTS BEFORE LEUKAPHERESIS FOR CAR-T CELL THERAPY.
por: Farina, M., et al.
Publicado: (2022)

P887: IN-HOUSE ANTI BCMA CAR-T THERAPY FOR THE TREATMENT OF RELAPSED REFRACTORY MULTIPLE MYELOMA: PHASE 1 RESULTS.
por: Asherie, N., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4uj1ipbj86gsjgmpg4p1lnel3f